A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
NCT07213960
Pegcetacoplan is under investigation for the treatment of focal segmental glomerulosclerosis (FSGS), a heterogeneous disorder characterized by histopathological lesions that are associated with glomerular basement membrane dysfunction. These lesions may result in glomerular scarring, proteinuria, and tubular inflammation, and ultimately, end-stage kidney disease. Although the causes underlying the FSGS pattern of injury vary across primary, genetic, and undetermined-cause FSGS, complement activation has been implicated in contributing to further kidney damage.
How is pegcetacoplan being studied in FSGS?
NCT07213960 is a sequential Phase 2/3 study to evaluate the efficacy and safety of pegcetacoplan in patients with FSGS. The initial Phase 2 portion, which is now enrolling, is a single-arm, open-label study in adults with FSGS. Phase 2 will begin before randomization starts for Phase 3. The Phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, global study in adults and adolescents with FSGS.
The Phase 2 portion of this multicenter, open-label study of pegcetacoplan will enroll approximately 15 adults with biopsy-confirmed primary, genetic, or undetermined-cause FSGS from various sites across the US. Participants will self-administer twice-weekly subcutaneous infusions of pegcetacoplan (1080 mg/20 mL).
The planned length of participation in Phase 2 for each participant is a maximum of approximately 120 weeks and will consist of 3 parts:
Up to 8-week screening period
104-week open-label period
8-week follow-up period
The primary outcome measure for Phase 2 is log-transformed ratio of urine protein-to-creatinine ratio (UPCR) at Week 12 (and exploratory endpoint at Week 104) compared with baseline, based on triplicate first morning urine (FMU).
Key Eligibility Criteria for Phase 2:
Adults (≥ 18 years) with primary, genetic, or undetermined-cause FSGS diagnosed by kidney biopsy
Weight ≥ 30 kg and ≤ 120 kg at screening with a body mass index ≤ 40 kg/m2
Proteinuria ≥ 1.5 mg/mg on a screening 24-hour urine collection or UPCR of ≥ 1.5 mg/mg in ≥ 2 FMU samples collected during screening
Estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2
Stable treatment for FSGS (may include renin-angiotensin-aldosterone system [RAAS] inhibitors and/or immunosuppressants) for ≥ 12 weeks with no planned or anticipated adjustments or dose changes to the stable treatment regimen
Have received pneumococcal and meningococcal vaccinations as per Advisory Committee on Immunization Practices (ACIP) recommendations prior to initiating trial treatment and, if required, have received approved antibiotic prophylaxis
No history of kidney transplant
Link to Study Website

Enroll in this study
Apellis (now part of Biogen)
Clinical Trial Information Line
833-284-6361
clinicaltrials@apellis.com